• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

219.01 +3.70 (+1.72%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jun 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
June 04, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
June 03, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
May 29, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
May 28, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
May 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
May 21, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
May 21, 2026
From Natera, Inc.
Via Business Wire
News headline image
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
May 20, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports First Quarter 2026 Financial Results
May 07, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its First Quarter Results on May 7, 2026
April 30, 2026
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
April 22, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
April 13, 2026
From Natera, Inc.
Via Business Wire
News headline image
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents
April 09, 2026
From Natera, Inc.
Via Business Wire
News headline image
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform
April 07, 2026
From Natera, Inc.
Via Business Wire
News headline image
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
March 31, 2026
From Natera, Inc.
Via Business Wire
News headline image
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
March 16, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
March 12, 2026
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
February 27, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
February 24, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026
February 17, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
February 06, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Submits Signatera™ CDx PMA to FDA
February 02, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
January 28, 2026
From Natera, Inc.
Via Business Wire
News headline image
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
January 26, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
January 21, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
January 20, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
January 13, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
January 12, 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
January 11, 2026
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap